NVS
Novartis AG
$159.85
+3.74
(+2.40%)
Mkt Cap
303.83B
Volume
1,626,942
52W Range
112.34-170.46
Sector
Healthcare
Beta
0.49
EPS (TTM)
6.66
P/E Ratio
24.00
Revenue (TTM)
55.63B
Rev Growth (5Y)
+1.9%
EPS Growth (5Y)
+15.4%
AlphaVal · Fair Value
What we estimate one share is worth
$131.87
Overvalued
moderate signal
21.2% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B+
Stable Earnings Power
78.1 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.81B | 51.72B | 46.66B | 43.46B | 43.97B | 49.90B | 48.68B | 46.10B | 43.40B | 49.44B | 50.39B | 53.63B |
| Net Income | 14.06B | 11.94B | 14.85B | 6.96B | 24.02B | 8.07B | 11.73B | 12.61B | 7.70B | 6.71B | 17.78B | 10.21B |
| EPS | 7.25 | 5.92 | 7.15 | 3.19 | 10.71 | 3.54 | 3.12 | 5.44 | 3.28 | 2.82 | 7.40 | 4.21 |
| Free Cash Flow | 17.69B | 13.80B | 11.71B | 12.00B | 12.52B | 11.06B | 11.37B | 10.92B | 9.88B | 8.60B | 8.05B | 10.19B |
| FCF / Share | 9.12 | 6.84 | 5.64 | 5.50 | 5.58 | 4.86 | 4.96 | 4.71 | 4.21 | 3.61 | 3.35 | 4.20 |
| Operating CF | 19.24B | 17.62B | 14.46B | 14.24B | 15.07B | 13.65B | 13.62B | 14.27B | 12.62B | 11.47B | 11.90B | 13.90B |
| Total Assets | 115.57B | 102.25B | 99.94B | 117.45B | 131.79B | 132.19B | 118.41B | 145.56B | 133.08B | 130.12B | 131.56B | 125.39B |
| Total Debt | 37.03B | 31.26B | 26.35B | 27.91B | 31.02B | 37.85B | 29.15B | 32.09B | 28.43B | 23.80B | 21.93B | 20.41B |
| Cash & Equiv | 11.44B | 11.46B | 13.39B | 7.52B | 12.41B | 9.66B | 11.11B | 13.27B | 8.86B | 7.01B | 4.67B | 13.02B |
| Book Value | 46.13B | 44.05B | 46.67B | 59.34B | 67.66B | 56.60B | 55.47B | 78.61B | 74.17B | 74.83B | 77.05B | 70.77B |
| Return on Equity | 0.30 | 0.27 | 0.32 | 0.12 | 0.36 | 0.14 | 0.21 | 0.16 | 0.10 | 0.09 | 0.23 | 0.14 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.42B | 13.52B | 13.33B | 14.36B | 14.84B | 13.62B | 13.56B | 13.17B | 12.87B | 12.12B | 11.78B | 12.09B |
| Net Income | 3.27B | 3.16B | 2.41B | 3.93B | 4.04B | 3.61B | 2.82B | 3.19B | 3.25B | 2.69B | 8.48B | 1.76B |
| EPS | 1.71 | 1.65 | 1.26 | 2.04 | 2.07 | 1.83 | 1.42 | 1.58 | 1.60 | 1.32 | 4.14 | 0.85 |
| Free Cash Flow | 5.57B | 2.87B | 1.64B | 5.74B | 6.11B | 2.15B | 3.06B | 5.49B | 4.15B | 1.11B | 2.14B | 5.26B |
| FCF / Share | 2.92 | 1.50 | 0.86 | 2.98 | 3.13 | 1.09 | 1.54 | 2.73 | 2.04 | 0.54 | 1.04 | 2.55 |
| Operating CF | 5.89B | 3.68B | 2.25B | 6.57B | 6.66B | 3.65B | 4.19B | 6.29B | 4.88B | 2.27B | 2.55B | 5.38B |
| Total Assets | 122.03B | 118.53B | 115.57B | 107.29B | 104.39B | 99.94B | 102.25B | 103.52B | 97.50B | 94.33B | 103.82B | 112.70B |
| Total Debt | 49.01B | 47.00B | 37.11B | 32.02B | 32.64B | 31.27B | 31.26B | 32.16B | 28.99B | 27.28B | 26.35B | 25.19B |
| Cash & Equiv | 7.62B | 6.88B | 11.44B | 9.56B | 6.66B | 7.07B | 11.46B | 13.61B | 7.90B | 9.47B | 13.39B | 12.40B |
| Book Value | 41.54B | 38.51B | 46.13B | 44.33B | 41.98B | 38.37B | 44.05B | 43.32B | 41.73B | 39.67B | 46.67B | 38.16B |
| Return on Equity | 0.08 | 0.08 | 0.05 | 0.09 | 0.10 | 0.09 | 0.06 | 0.07 | 0.08 | 0.07 | 0.18 | 0.05 |
NVS News
Novartis: The Buy Thesis Is Back (Rating Upgrade)
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
Novartis CEO on 2Q Profit Beat, Investing in Pipeline
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well
Q2 Earnings Pick Up Steam: GM, MMM, DHI & More
Novartis Q2 Earnings Call Highlights
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics
5 Things to Know Before the Stock Market Opens on Tuesday
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
Novartis CEO Vas Narasimhan says 'no change of plans'